

해외 바이오의약품 임상 현황 (2020.03.09~2020.03.15)

한국바이오의약품협회, 2020.3.17.
출처: ClinicalTrials.gov

○ 미국 20건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03735589	Specialized Immune Cells (nCTLs) and Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage IIA Fallopian Tube Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA Primary Peritoneal Cancer AJCC v8 Stage IIB Fallopian Tube Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIB Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8	Biological: Alpha-type-1 Polarized Dendritic Cells Biological: Autologous Natural Killer Cell-like CTLs	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT02057159	A Study of NeuroVax?? a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	Secondary Progress Multiple Sclerosis Multiple Sclerosis	Biological: NeuroVax Biological: IFA Placebo	Immune Response BioPharma, Inc. cro	Phase 2 Phase 3
NCT04309084	Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma	Multiple Myeloma Neoplasm, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorder Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs	Biological: CYNK-001	Celularity Incorporated	Phase 1 Phase 2
NCT04303845	Erenumab For Treatment of Hemicrania Continua	Hemicrania Continua	Drug: Erenumab	Mayo Clinic	Phase 2
NCT04237623	GM-CSF With Post-Transplant Cyclophosphamide	Transplant-Related Hematologic Malignancy	Drug: Sargramostim Other: Control Arm	Northside Hospital, Inc.	Phase 2
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Aggressive Non-Hodgkin Lymphoma ALK-Positive Large B-Cell Lymphoma B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Primary Mediastinal (Thymic) Large B-Cell Lymphoma T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	Drug: Polatuzumab Vedotin Biological: Rituximab Drug: Prednisone Drug: Etoposide Drug: Doxorubicin Drug: Cyclophosphamide Biological: Filgrastim	University of Washington National Cancer Institute (NCI) Genentech, Inc.	Phase 1
NCT04203875	Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis	Autoimmune Hepatitis	Drug: Orencia (Abatacept)	Stuart Knechtle, M.D. Duke University	Phase 1
NCT04195945	CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients	Acute Myeloid Leukemia Myeloid Neoplasm	Drug: Liposome-encapsulated Daunorubicin-Cytarabine Drug: Cladribine Drug: Cytarabine Biological: Granulocyte Colony-Stimulating Factor Drug: Mitoxantrone Other: Questionnaire Administration Other: Quality-of-Life Assessment	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Jazz Pharmaceuticals	Phase 2
NCT04179175	Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa	Hidradenitis Suppurativa	Drug: secukinumab	Novartis Pharmaceuticals Novartis	Phase 3
NCT04139902	PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042)	Melanoma Stage III Melanoma Stage IV	Drug: Dostarlimab (TSR-042) (singly) Drug: Dostarlimab (TSR-042) and TSR-022 (combination)	Diwakar Davar Tesaro, Inc. University of Pittsburgh	Phase 2
NCT04120246	Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 ERBB2 Overexpression HER2 Positive Breast Carcinoma Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Refractory Breast Carcinoma	Drug: Alpha-tocopheryloxyacetic Acid Biological: Trastuzumab	University of Washington National Cancer Institute (NCI) Veana Therapeutics, Inc.	Phase 1
NCT04099836	Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib	Non Small Cell Lung Cancer	Drug: Atezolizumab Drug: Bevacizumab	Duke University	Phase 2

해외 바이오의약품 임상 현황 (2020.03.09~2020.03.15)

한국바이오의약품협회, 2020.3.17.
출처: ClinicalTrials.gov

NCT02149706	A Study of NeuroVax?? a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	Multiple Sclerosis	Biological: NeuroVax Biological: IFA Incomplete Freund's Adjuvant	Immune Response BioPharma, Inc. cro	Phase 2
NCT03938792	Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B	Hemophilia A Hemophilia B	Drug: PF-06741086	Pfizer	Phase 3
NCT04098250	Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH	Post-Traumatic Headache	Drug: Erenumab Other: Placebo	Mayo Clinic University of Arizona Translational Genomics Research Institute Arizona State University Phoenix VA Health Care System United States Department of Defense Amgen	Phase 2
NCT04250155	An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Solid Tumors	Drug: XmAb24306 Drug: Atezolizumab	Genentech, Inc.	Phase 1
NCT04210375	Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)	Heart Failure With Reduced Ejection Fraction	Drug: JK07 Drug: Matching Placebo	Salubris Biotherapeutics Inc	Phase 1
NCT04287179	SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: Semaglutide	Novo Nordisk A/S	Phase 3
NCT04136171	CARDIO-TTRransform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Transthyretin?mediated Amyloid Cardiomyopathy (ATTR CM)	Transthyretin?mediated Amyloid Cardiomyopathy (ATTR CM)	Drug: AKCEA-TTR-LRx Drug: Placebo	Ionis Pharmaceuticals, Inc. Akcea Therapeutics	Phase 3
NCT04206605	Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH Deficiency	Angioedema	Drug: Lanadelumab Other: Placebo	Shire	Phase 3

○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04289220	Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia	B Cell Lymphoma B-cell Acute Lymphoblastic Leukemia	Biological: Anti-CD19 CAR-T Cells Injection	Yan'an Affiliated Hospital of Kunming Medical University	Phase 1
NCT04190823	A Study of RC98 in Subjects With Advanced Malignant Solid Tumors	Solid Tumors	Drug: RC98	RemeGen	Phase 1
NCT04070040	Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)	Primary Central Nervous System Lymphoma	Drug: Camrelizumab	Beijing Sanbo Brain Hospital	Phase 2
NCT04285229	A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis	Spondyloarthritis	Drug: Ixekizumab Drug: Placebo	Eli Lilly and Company	Phase 3

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04306302	A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults	Healthy	Biological: ExPEC10V Biological: Placebo	Janssen Pharmaceutical K.K.	Phase 1
NCT04181788	PF-06801591 (PD-1 Inhibitor) in Participants With Advanced Malignancies	Advanced Malignancies Non-small-cell Lung Cancer	Drug: PF-06801591	Pfizer	Phase 2